Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 1

Status

Recruiting 21Not yet recruiting 10Active not recruiting 5Completed 3Withdrawn 1Enrolling by invitation 1

Sponsor Class

OTHER 2INDUSTRY 2NETWORK 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 5

Conditions

Pancreatic Neoplasms 3Gastrointestinal Neoplasms 1Esophageal Neoplasms 1Biliary Tract Neoplasms 1

Interventions

pembrolizumab 374Carboplatin 276Specimen Handling 265Nivolumab 252Magnetic Resonance Spectroscopy 244Cyclophosphamide 240Cisplatin 213Paclitaxel 206Radiotherapy 195Biopsy 171Gemcitabine 155Dexamethasone 148durvalumab 143atezolizumab 126Rituximab 120Doxorubicin 115Bevacizumab 114Lenalidomide 113Ipilimumab 111Radiation 109Docetaxel 103Pemetrexed 102Etoposide 101fludarabine 97venetoclax 95Fluorouracil 92Capecitabine 92Radiosurgery 90Prednisone 89Oxaliplatin 89

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Active not recruiting × irinotecan sucrosofate × 1 year × Clear all
NCT06625320 2026-06-02

RASolute 302

Revolution Medicines, Inc.

Phase 3 Active not recruiting
500 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT04233866 2026-05-05

Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread

Eastern Cooperative Oncology Group

Phase 2 Active not recruiting
176 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT03764553 2026-04-07

LyRICX

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Phase 2 Active not recruiting
320 enrolled
Gastrointestinal

Esophageal Neoplasms

NCT04005339 2026-01-26

NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer

Georgetown University

Phase 2 Active not recruiting
48 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Gastrointestinal Neoplasms

NCT04390399 2025-12-15

Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer

ImmunityBio, Inc.

Phase 2 Active not recruiting
328 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡